Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: New prognostic markers are needed to identify patients with hepatocellular carcinoma (HCC) who carry a worse prognosis. Ultra-low-pass whole-genome sequencing (ULP-WGS) (≤0.5× coverage) of cell-free DNA (cfDNA) has emerged as a low-cost promising tool to assess both circulating tumor DNA (ctDNA) fraction and large structural genomic alterations. Here, we studied the performance of ULP-WGS of plasma cfDNA to infer prognosis in patients with HCC. Methods: Plasma samples were obtained from patients with HCC prior to surgery, locoregional or systemic therapy, and were analyzed by ULP-WGS of cfDNA to an average genome-wide fold coverage of 0.3x. ctDNA and copy number alterations (CNA) were estimated using the software package ichorCNA. Results: Samples were obtained from 73 HCC patients at different BCLC stages (BCLC 0/A: n=37, 50.7%; BCLC B/C: n=36, 49.3%). ctDNA was detected in 18 out of 31 patients who received systemic treatment. Patients with detectable ctDNA showed significantly worse overall survival (median, 13.96 months vs not reached). ctDNA remained an independent predictor of prognosis after adjustment by clinical-pathologic features and type of systemic treatment (hazard ratio 7.69; 95%, CI 2.09–28.27). Among ctDNA-positive patients under systemic treatments, the loss of large genomic regions in 5q and 16q arms was associated with worse prognosis after multivariate analysis. Conclusions: ULP-WGS of cfDNA provides clinically relevant information about the tumor biology. The presence of ctDNA and the loss of 5q and 16q arms in ctDNA-positive patients are independent predictors of worse prognosis in patients with advanced HCC receiving systemic therapy.
Abstract
Background/Aims: New prognostic markers are needed to identify patients with hepatocellular carcinoma (HCC) who carry a worse prognosis. Ultra-low-pass whole-genome sequencing (ULP-WGS) (≤0.5× coverage) of cell-free DNA (cfDNA) has emerged as a low-cost promising tool to assess both circulating tumor DNA (ctDNA) fraction and large structural genomic alterations. Here, we studied the performance of ULP-WGS of plasma cfDNA to infer prognosis in patients with HCC. Methods: Plasma samples were obtained from patients with HCC prior to surgery, locoregional or systemic therapy, and were analyzed by ULP-WGS of cfDNA to an average genome-wide fold coverage of 0.3x. ctDNA and copy number alterations (CNA) were estimated using the software package ichorCNA. Results: Samples were obtained from 73 HCC patients at different BCLC stages (BCLC 0/A: n=37, 50.7%; BCLC B/C: n=36, 49.3%). ctDNA was detected in 18 out of 31 patients who received systemic treatment. Patients with detectable ctDNA showed significantly worse overall survival (median, 13.96 months vs not reached). ctDNA remained an independent predictor of prognosis after adjustment by clinical-pathologic features and type of systemic treatment (hazard ratio 7.69; 95%, CI 2.09–28.27). Among ctDNA-positive patients under systemic treatments, the loss of large genomic regions in 5q and 16q arms was associated with worse prognosis after multivariate analysis. Conclusions: ULP-WGS of cfDNA provides clinically relevant information about the tumor biology. The presence of ctDNA and the loss of 5q and 16q arms in ctDNA-positive patients are independent predictors of worse prognosis in patients with advanced HCC receiving systemic therapy.
참고문헌 (40)
- Llovet JM, "Hepatocellular carcinoma", Nat Rev Dis Primers, 7, pp.6~ (2021)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Reig M, "BCLC strategy for prognosis prediction and treatment recommendation : The 2022 update", J Hepatol, 76, pp.681~693 (2022)
- Bolondi L, "Heterogeneity of patients with intermediate(BCLC B)Hepatocellular Carcinoma : proposal for a subclassification to facilitate treatment decisions", Semin Liver Dis, 32, pp.348~359 (2012)
- D’Avola D, "Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages", Ann Surg Oncol, 18, pp.1964~1971 (2011)
- Ferrer-Fàbrega J, "Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection", Hepatology, 63, pp.839~849 (2016)
- "Paper presented at: American Association for Cancer Research (AACR) Annual Conference", 2023, ~
- Duvoux C, "Liver transplantation for hepatocellular carcinoma : a model including α-fetoprotein improves the performance of Milan criteria", Gastroenterology, 143, pp.986~994 (2012)
- Zhu AX, "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2) : a randomised, double-blind, placebocontrolled, phase 3 trial", Lancet Oncol, 20, pp.282~296 (2019)
- Singal AG, "International Liver Cancer Association(ILCA)white paper on biomarker development for hepatocellular carcinoma", Gastroenterology, 160, pp.2572~2584 (2021)
- Montal R, "Molecular portrait of high alphafetoprotein in hepatocellular carcinoma : implications for biomarker-driven clinical trials", Br J Cancer, 121, pp.340~343 (2019)
- Tanabe N, "Early prediction of response focused on tumor markers in atezolizumab plus bevacizumab therapy for hepatocellular carcinoma", Cancers(Basel), 15, pp.2927~ (2023)
- von Felden J, "Liquid biopsy in the clinical management of hepatocellular carcinoma", Gut, 69, pp.2025~2034 (2020)
- Adalsteinsson VA, "Scalable whole-exome sequencing of cellfree DNA reveals high concordance with metastatic tumors", Nat Commun, 8, pp.1324~ (2017)
- Yu L, "Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels", PLoS One, 17, pp.e0266889~ (2022)
- Saelee P, "Allelic loss on chromosome 5q34 is associated with poor prognosis in hepatocellular carcinoma", J Cancer Res Clin Oncol, 134, pp.1135~1141 (2008)
- Niu ZS, "Genetic alterations in hepatocellular carcinoma : An update", World J Gastroenterol, 22, pp.9069~9095 (2016)
- Cai Z, "Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma", Clin Cancer Res, 25, pp.5284~5294 (2019)
- Wang Y, "Multiplelevel copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments", Cancer Sci, 112, pp.4772~4784 (2021)
- Chat V, "Ultra low-coverage whole-genome sequencing as an alternative to genotyping arrays in genome-wide association studies", Front Genet, 12, pp.790445~ (2022)
- Dong X, "Copy number profiling of circulating free DNA predicts transarterial chemoembolization response in advanced hepatocellular carcinoma", Mol Oncol, 16, pp.1986~1999 (2022)
- Cancer Genome Atlas Research Network, "Comprehensive and integrative genomic characterization of hepatocellular carcinoma", Cell, 169, pp.1327~1341 (2017)
- Chen X, "Low-pass whole-genome sequencing of circulating cell-free DNA demonstrates dynamic changes in genomic copy number in a squamous lung cancer clinical cohort", Clin Cancer Res, 25, pp.2254~2263 (2019)
- Shulman DS, "Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma : a report from the Children’s Oncology Group", Br J Cancer, 119, pp.615~621 (2018)
- Nørgaard M, "Prognostic value of low-pass whole genome sequencing of circulating tumor DNA in metastatic castration-resistant prostate cancer", Clin Chem, 69, pp.386~398 (2023)
- Abbas A, "Case report : Circulating tumor DNA fraction analysis using ultra-low-pass whole-genome sequencing correlates response to chemoradiation and recurrence in stage IV smallcell carcinoma of the cervix-A longitudinal study", Front Oncol, 11, pp.652683~ (2021)
- Stover DG, "Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer", J Clin Oncol, 36, pp.543~553 (2018)
- Bruix J, "Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma", Gastroenterology, 150, pp.835~853 (2016)
- Wang B, "The expression profiles and prognostic values of HSP70s in hepatocellular carcinoma", Cancer Cell Int, 21, pp.286~ (2021)
- Di Tommaso L, "Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis", Hepatology, 45, pp.725~734 (2007)
- Hennigan ST, "Low abundance of circulating tumor DNA in localized prostate cancer", JCO Precis Oncol, 3, pp.PO.19.00176~ (2019)
- Jahr S, "DNA fragments in the blood plasma of cancer patients : quantitations and evidence for their origin from apoptotic and necrotic cells", Cancer Res, 61, pp.1659~1665 (2001)
- Kan Z, "Wholegenome sequencing identifies recurrent mutations in hepatocellular carcinoma", Genome Res, 23, pp.1422~1433 (2013)
- Zhao Z, "Genomic losses at 5q13. 2and 8p23. 1 in dysplastic hepatocytes are common events in hepatitis B virus-related hepatocellular carcinoma", Oncol Lett, 9, pp.2839~2846 (2015)
- Raidl M, "Multiple chromosomal abnormalities in human liver(pre)neoplasia", J Hepatol, 40, pp.660~668 (2004)
- Chen J, "Prognostic significance of E-cadherin expression in hepatocellular carcinoma : a meta-analysis", PLoS One, 9, pp.e103952~ (2014)
- Mínguez B, "Pathogenesis of hepatocellular carcinoma and molecular therapies", Curr Opin Gastroenterol, 25, pp.186~194 (2009)
- Kuroki T, "Evidence for the presence of two tumour-suppressor genes for hepatocellular carcinoma on chromosome 13q", Br J Cancer, 72, pp.383~385 (1995)
- Bakhoum SF, "The multifaceted role of chromosomal instability in cancer and its microenvironment", Cell, 174, pp.1347~1360 (2018)
- Sansregret L, "Determinants and clinical implications of chromosomal instability in cancer", Nat Rev Clin Oncol, 15, pp.139~150 (2018)